| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 2.1, positive 2.8, negative -0.8) on 20251106. The forces of Price Level (2), Sentiment towards Fundamentals (1.8), Option Speculation (1.5), Sector Price Trend (0.3), and Broad Market Trend (-0.5) will drive up the price. The forces of Valuation Sentiment (-1), and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (2.8). The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-06 | 2% | 1.9% | 145.92 | 76 | 0.19% | -0.07% | 0.4 | 0.3 | 1.8 | 2.4 |
| 2025-11-05 | 2% | 2% | 145.64 | 74 | 0.43% | 0% | 0.7 | 0.1 | 1.9 | 1.2 |
| 2025-11-04 | 3% | 1.9% | 145.01 | 65 | 0.42% | 0% | 0.6 | -0.1 | 1.9 | 4.4 |
| 2025-11-03 | 2% | 1.7% | 144.41 | 54 | 0.12% | 0% | 0.3 | -0.5 | 1.7 | 2.7 |
| 2025-11-02 | 1% | 1.6% | 1.2 | -0.3 | 1.8 | 0 | ||||
| 2025-11-01 | 1% | 1.6% | 1.1 | -0.3 | 1.7 | 1.5 | ||||
| 2025-10-31 | 2% | 1.4% | 144.23 | 51 | -0.05% | 0.07% | 1.1 | -0.3 | 1.7 | 3.5 |
| 2025-10-30 | 3% | 1.3% | 144.3 | 52 | 0.17% | 0.14% | 1.1 | -0.4 | 2 | 4.9 |
| 2025-10-29 | 1% | 1% | 144.05 | 47 | -0.95% | 0.07% | 1.7 | -0.4 | 2.1 | -0.9 |
| 2025-10-28 | 2% | 1% | 145.44 | 74 | -0.65% | 0.21% | 1.8 | 0.2 | 2 | 5.2 |
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (2) Trump rolls out pricing deal with weight-loss-drug giants Eli Lilly, Novo Nordisk. Analysts say the pact raises more questions than it answers. The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.gov, the administration’s new direct-to-consumer website. (https://www.marketwatch.com/) Thu. Nov 6, 2025 | |
| 2 (-8) Teleflex Shares Drop 12% After Posting Q3 Loss Teleflex Incorporated (TFX) shares fell 12.2 percent to $109.57 on Thursday after the company reported a steep third-quarter loss driven by charges that swung results from a profit a year ago. (https://www.rttnews.com/) Thu. Nov 6, 2025 | |
| 3 (6) Haemonetics Stock Jumps 27% After Mixed Q2 Results Haemonetics Corporation (HAE) shares surged 27.3 percent to $64.58 on Thursday after the medical technology company posted higher quarterly earnings and raised parts of its fiscal 2026 revenue outlook, despite reporting a decline in sales. (https://www.rttnews.com/) Thu. Nov 6, 2025 | |
| 4 (7) Startup Omada Health to start prescribing GLP-1s, other obesity medications as membership grows The announcement expands the offerings under the company's weight management program as its membership grows to more than 800,000. (https://www.cnbc.com/) Thu. Nov 6, 2025 | |
| 5 (5) Mark Cuban tips his hat to longtime foe Donald Trump for TrumpRx deal with Eli Lilly and Novo Nordisk President Trump promised to lower the cost of Ozempic. Mark Cuban says he's working from the same playbook as Cost Plus, giving consumers transparent prices. (https://www.businessinsider.com/) Thu. Nov 6, 2025 | |
| 6 (5) Novo Nordisk Sweetens Bid for Obesity Drug Startup Metsera Novo Nordisk A/S has again increased its offer for Metsera Inc. as its takeover battle with Pfizer Inc. for the obesity startup escalates. (https://www.bloomberg.com/) Thu. Nov 6, 2025 | |
| 7 (-3) Eli Lilly, Novo to cut GLP-1 cost; airline stocks fall on FAA cut Yahoo Finance's John Hyland tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly (LLY) and Novo Nordisk (NVO) will lower GLP-1 prices as a result of newly made agreements with the Trump administration. Airline stocks, including United (UAL), American (AAL), and Delta (DAL), are falling after the FAA announced a 10% decrease in flight traffic amid the government shutdown. Ralph Lauren (RL) stock is under pressure even after the company reported second quarter results that topped analyst estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. (https://finance.yahoo.com/) Thu. Nov 6, 2025 | |
| 8 (1) Moderna's losses narrow, Coach-maker's outlook disappoints Yahoo Finance anchor Josh Lipton recaps three of the top stories investors are watching as part of Yahoo Finance's Market Minute, including Vistra's (VST) revenue miss, Moderna's (MRNA) narrower-than-expected loss, and Tapestry's (TPR) weak outlook. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. (https://finance.yahoo.com/) Thu. Nov 6, 2025 | |
| 9 (2) Wall Street Banks Weigh Tapping Private Credit on Hologic $12 Billion Debt Deal A group of Wall Street banks are considering bringing in private credit firms on a portion of a $12.25 billion debt financing to support Blackstone Inc. and TPG Inc.’s acquisition of medical device-maker Hologic Inc., according to people with knowledge of the matter. (https://www.bloomberg.com/) Thu. Nov 6, 2025 | |
| 10 (3) Cramer's favorite drug stock should be higher — plus, what’s behind the market selloff The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. (https://www.cnbc.com/) Thu. Nov 6, 2025 | |
| 11 (-7) Peloton recalls 833,000 bikes after reports of injuries The Consumer Product Safety Commission is warning Peloton users to stop using the affected bikes immediately. (https://finance.yahoo.com/) Thu. Nov 6, 2025 | |
| 12 (5) Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter. (https://finance.yahoo.com/) Thu. Nov 6, 2025 | |
| 13 (4) Obamacare Insurer Oscar Health Sees 2026 ‘Return To Profitability’ Oscar Health reported a $137 million loss but predicts a 2026 return to profitability as health insurers work through a period of rising costs and Washington gridlock. (https://www.forbes.com/) Thu. Nov 6, 2025 | |
| 14 (8) AstraZeneca CEO bullish on record revenue numbers and US growth AstraZeneca's (AZN, AZN.L, AZN.ST) Q3 revenues surpassed $15 billion thanks to soaring sales of cancer drugs. CEO Pascal Soriot told Market Sunrise host Ramzan Karmali that the drugmaker has big plans to expand in the US to win market share. The Anglo-Swedish firm faces fierce competition from the likes of Johnson & Johnson (JNJ), Merck (MRK) and Pfizer (PFE). For more live coverage of the markets, watch the full episode of Market Sunrise and visit Yahoo Finance. (https://finance.yahoo.com/) Thu. Nov 6, 2025 | |
| 15 (3) Moderna Gains on Sharp Cost Cuts as Covid Vaccine Declines The company posted a net loss of 51 cents a share, against Wall Street’s expectation for a loss of $2.21. Moderna has aggressively reduced costs through measures including staff cuts and lower spending on research and manufacturing to offset slowing vaccine sales. The company still has a goal of breaking even by 2028, Moderna Chief Financial Officer Jamey Mock said in an interview. (https://finance.yahoo.com/) Thu. Nov 6, 2025 | |
| 16 (6) Earnings live: Moderna stock pops amid cost-cutting efforts, Snap stock soars, Duolingo plunges Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter. (https://finance.yahoo.com/) Thu. Nov 6, 2025 | |
| 17 (-6) Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic Novo Nordisk cuts its outlook as it sees slowing demand for its GLP-1 weight loss and diabetes treatments. (https://www.investopedia.com/) Wed. Nov 5, 2025 | |
| 18 (8) Jazz Pharmaceuticals Plc Reveals Advance In Q3 Bottom Line Jazz Pharmaceuticals plc (JAZZ) reported earnings for its third quarter that Increases, from the same period last year The company's bottom line totaled $251. (https://www.rttnews.com/) Wed. Nov 5, 2025 | |
| 19 (-5) Pfizer Loses Legal Bid to Temporarily Block Novo’s Metsera Offer A judge denied Pfizer Inc.’s request to temporarily block Novo Nordisk A/S’ $10 billion bid to acquire the obesity startup Metsera Inc., saying the US pharmaceutical company’s objections to the deal don’t warrant a delay. (https://www.bloomberg.com/) Wed. Nov 5, 2025 | |
| 20 (2) Apple's reported Google deal, Teva & Axon post-earnings moves Market Domination host Josh Lipton examines some of Wednesday's trending tickers. Apple (AAPL) is reportedly nearing a deal with Alphabet (GOOG, GOOGL) to overhaul Siri, according to Bloomberg. Teva (TEVA) stock rose after the company reported earnings, while Axon (AXON) stock fell after the company's quarterly results missed estimates. To watch more expert insights and analysis on the latest market action, check out more Market Domination. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 21 (2) GLP-1 goliath updates demand for top weight loss drug A weight-loss giant reports Q3 earnings, causing a stock swing. (https://www.thestreet.com/) Wed. Nov 5, 2025 | |
| 22 (-5) FTC Staff Raise Questions About Novo Bid for Metsera Staff members at the US Federal Trade Commission said it appears Novo Nordisk A/S’ proposed bid for Metsera Inc. “may violate the procedural provisions” of the law that requires a premerger review. (https://www.bloomberg.com/) Wed. Nov 5, 2025 | |
| 23 (8) Tempus AI Growth Outlook Boosted By Higher ASPs, Pharma Contracts, Analyst Says Tempus AI beats Q3 revenue estimates with $334.21M, narrows adjusted loss to $0.11 per share, and raises FY25 guidance to $1.265B. (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 24 (0) 10 Health Care Stocks Whale Activity In Today's Session (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 25 (-6) Novo Nordisk downgrades sales outlook again amid bidding war with Pfizer for Metsera Management lowers full-year guidance, warns about competition, launches bid for Metsera. (https://www.marketwatch.com/) Wed. Nov 5, 2025 | |
| 26 (8) Elanco Shares Poised For Upside After Another Quarter Of Outperformance Elanco posts strong Q3 results with 10% sales growth, surpasses forecasts, and raises full-year revenue and earnings guidance for 2025. (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 27 (2) Humana Q3 Premium Growth Offsets Membership Drop, Stock Tumbles Humana beat Q3 estimates with $3.24 EPS and $32.65 billion sales, reaffirming 2025 earnings guidance at $17 per share despite Medicare declines. (https://www.benzinga.com/) Wed. Nov 5, 2025 | |
| 28 (-7) Novo Nordisk cuts outlook, IBM layoffs, Pinterest stock plummets Yahoo Finance Senior Reporter Allie Canal takes a closer look at some of Wednesday's trending tickers, including Novo Nordisk (NVO), IBM (IBM), and Pinterest (PINS). To watch more expert insights and analysis on the latest market action, check out more Morning Brief. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 29 (5) Rivian tops Q3 estimates, Humana stock sinks on high medical costs Yahoo Finance Senior Reporter Allie Canal takes a look at some of Wednesday's trending tickers and stories. Rivian (RIVN) beat on third quarter earnings results. Humana (HUM) stock is under pressure after the company warned that medical costs are higher than usual. Unity Software (U) stock is surging after the company released third quarter results that beat expectations. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 30 (7) Humana Reports $195 Million Profit As Costs Land Within Expectations Humana reported $195 million in third quarter profits as the health insurer’s medical cost trends were in line with forecasts for the provider of Medicare Advantage. (https://www.forbes.com/) Wed. Nov 5, 2025 | |
| 31 (8) Humana beats quarterly profit estimates on higher premiums, in-line medical costs () -Humana reported third-quarter profit that beat Wall Street estimates on Wednesday, helped by higher premiums and medical costs which were in line with the health insurer's expectations. The company is one of the largest providers of Medicare Advantage plans, under which the U. (https://finance.yahoo.com/) Wed. Nov 5, 2025 | |
| 32 (-7) Humana’s stock falls as Medicaid, health-benefit costs are still problems Medicaid-membership growth outlook was slashed, and as medical costs are still a problem. (https://www.marketwatch.com/) Wed. Nov 5, 2025 | |
| 33 (7) CSL Predicts US Flu-Shot Rebound as Seqirus Expands in Europe CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. (https://www.bloomberg.com/) Wed. Nov 5, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA